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To date, numerous genes have been identiﬁed which are involved in both tumour neovascularisation (angiogenesis) and
tumour cell invasion, and most of them are also expressed to some extent under normal physiological conditions. However,
little is known about how these genes co-express in these settings. This study was undertaken to quantitate mRNA levels in
normal and malignant cervical tissues of nine selected genes (VEGF121, VEGF165, VEGF189, VEGF-C, eIF-4E, b-FGF, TSP-2,
MMP-2 and MMP-9) implicated in the above processes using real-time quantitative RT–PCR. In addition, the Spearman’s rank
correlation was used to determine their co-expression patterns. The transcript levels for the different VEGF-A splice variants
(VEGF121, VEGF165, VEGF189) were at least 10-fold higher in the cancer cases, with the highest levels in the primary tumours
demonstrating lympho-vascular space involvement. The lymphangiogenic factor VEGF-C and MMP-9 were upregulated 130-
and 80-fold respectively in cervical cancers. The highest levels of VEGF-C mRNA were found in the lymph-node positive
group. The transcript levels for b-FGF were similar in normal cervical tissue and early-stage cervical cancer, however, higher
levels were found in the cervical cancers with advanced stage disease. Comparing gene transcript levels between recurrent
and non-recurrent cervical cancer patients revealed signiﬁcant differences (P=0.038) in transcript levels for the angiogenesis
inhibitor TSP-2, with the highest levels in non-recurrent cases. Co-expression pattern analysis in normal cervical tissue revealed
highly signiﬁcant co-expressions (P50.0001) between TSP-2 and most other genes analysed (VEGF121, VEGF165, VEGF-C, b-
FGF and MMP-2). In cervical cancer, TSP-2 appears only to be highly co-expressed with MMP-2 (P50.0001). In contrast to
normal cervical tissue, we found a highly signiﬁcant co-expression (P50.0001) between MMP-9 and VEGF189 in cervical
cancer. The combined application of real-time quantitative RT–PCR and Spearman’s rank correlation identiﬁes gene
transcripts which are simultaneously co-expressed. Our results revealed a signiﬁcant co-expression between the angiogenesis
inhibitor TSP-2 and most other genes analysed in normal cervical tissue. In cervical cancer, we found a strong upregulation of
VEGF-C and MMP-9 mRNA, with a highly signiﬁcant co-expression between MMP-9 and VEGF189.
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During tumour progression, two phases can be recognised with
regard to neovascularization: a prevascular and a vascular phase.
The transition from one phase to the other is referred to as the
‘angiogenic switch’ (Folkman, 1971, 2000; Carmeliet and Jain,
2000; Hanahan and Folkman, 1996). The current working hypoth-
esis is that the ‘switch’ involves either the induction of a positive
regulator and/or the loss of a negative regulator. In the healthy
adult organism, endothelial cell turnover is very low. This is
thought to be due to the dominance of endogenous negative regu-
lators, since positive regulators are frequently detected in adult
tissues in which there is apparently no angiogenesis. Endogenous
negative regulators identiﬁed to date include members of the
thrombospondin (TSP) family, angiostatin and endostatin (Volpert
et al, 1995; O’Reilly et al, 1994, 1997). Among the positive endo-
genous regulators of tumour angiogenesis are the vascular
endothelial growth factor (VEGF) and ﬁbroblast growth factor
(FGF) families of cytokines.
Molecular cloning has revealed at least ﬁve different isoforms of
VEGF which are generated from a single mRNA by alternative spli-
cing, and which have signiﬁcantly different biochemical features
and biological effects (Ferrara et al, 1991; Houck et al, 1991; Veik-
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evidence in breast cancer patients that levels of VEGF-A mRNA
correlate with mRNA levels of the translation initiation factor
eIF-4E, implying co-regulation of these genes (Scott et al, 1998).
In several cancer types (breast, head and neck and prostate cancer)
eIF-4E causes increased translational efﬁciency of several oncogene
transcripts (e.g. cyclin D1 and c-Myc) and growth factors (e.g.
basic-FGF and VEGF), leading to overexpression of their products
(De Benedetti and Harris, 1999). Recent studies have shown that
the growth factor VEGF-C plays a crucial role in the growth of
lymphatic vessels (lymphangiogenesis), an effect which is mediated
in part through VEGFR-3 (Jeltsch et al, 1997; Lymboussaki et al,
1998).
Many biological processes, including angiogenesis and tumour
cell invasion, require extracellular proteolysis for degradation of
the extracellular matrix. This allows endothelial and tumour cells
to migrate through tissue stroma and subsequently to enter and
spread via the blood and/or lymphatic systems. The matrix metal-
loproteinases (MMPs), including MMP-2 and MMP-9 (gelatinase-
A and -B), are amongst the best studied proteases in this respect.
Enhanced mRNA and protein levels of both MMP-2 and MMP-9
have been detected in breast, colon and pancreatic cancer (Campo
et al, 1992). A recent study in transgenic mice suggests that MMP-
9 triggers the angiogenic switch during carcinogenesis (Bergers et
al, 2000).
Until recently, studies on angiogenesis in several cancers have
largely been limited to analysis of microvascular density (MVD).
However, little information is available regarding the co-expression
of genes implicated in angiogenesis in different tumour types. Both
angiogenesis and lymphangiogenesis are likely to be key processes
in disease progression in cervical malignancy, given the well docu-
mented pattern of direct spread through parametrial tissues,
lymphatic spread to pelvic lymph nodes, and haematogenous disse-
mination to distant organs. We have recently shown that
approximately 50% of early-stage cervical cancers shed tumour
cells to the pelvic lymph nodes (Van Trappen et al, 2001). The
lymphangiogenic factor VEGF-C may be a key element in this
process.
Recent technical advances have provided us with opportunities
to assess levels of gene transcription and to identify patterns of
co-expression. Although microarray technology can measure the
expression of thousands of genes simultaneously, it is a semi-quan-
titative technique (Schena et al, 1995; Eisen et al, 1998; Duggan et
al, 1999; Lander, 1999; Liotta and Petricoin, 2000). As the genes
involved in tumour angiogenesis are also expressed in normal
tissues, a real understanding of gene expression in carcinogenesis
requires an accurate and fully quantitative technique. Real-time
quantitative RT–PCR fulﬁls this requirement and has recently
been used to accurately quantitate transcription levels of a variety
of genes (Heid et al, 1996).
The aim in our study was to identify which genes are co-
expressed in tumours in which angiogenesis and/or lymphangio-
genesis are prominent, and to determine whether a different co-
expression pattern exists between normal and malignant cervical
tissue. Transcripts of the following nine genes were analysed:
VEGF121, VEGF165, VEGF189, VEGF-C, eIF-4E, basic-FGF (b-
FGF), TSP-2, MMP-2 and MMP-9.
MATERIALS AND METHODS
Patients and samples
The patient population consisted of 52 women of whom 34 had
malignant and 18 normal cervical tissue. Ethical approval was
obtained from the Local Research Ethics Committee of the East
London and City Health Authority. During the period between
January 1998 to March 2000, radical hysterectomy and pelvic
lymphadenectomy were carried out in 29 cervical cancer patients
with early-stage disease conﬁned to the uterus. Five patients were
treated with primary radiotherapy for advanced stage disease (stage
IIB–III) during the same time period, and cervical biopsies were
taken before radiotherapy. None of the cancer patients had under-
gone any previous treatment to the cervix. Tissue specimens were
taken from the periphery of the tumour, as it is known that
neovascular hot spots occur predominantly at tumour margins
(Tokumo et al, 1998). One portion was snap frozen for RT–
PCR analysis while a neighbouring portion was ﬁxed in 10%
formaldehyde for histological examination to determine whether
the biopsy specimen contained 480% tumour tissue. The histolo-
gical cell types of the 34 cervical cancers were assigned according to
the World Health Organisation (WHO) classiﬁcation: 23 were clas-
siﬁed as squamous cell carcinoma, 8 as adenocarcinoma, 2 as clear
cell carcinoma and 1 as carcinoid. Clinical staging was determined
using the International Federation of Gynaecology and Obstetrics
(FIGO) classiﬁcation: 6 were stage IA2, 15 were staged as stage
IB1, 6 were stage IB2, 2 were stage IIA, 3 were stage IIB, 2 were
stage III (Table 1: patient characteristics).
As controls, 18 biopsy specimens were obtained from normal
cervices from patients who underwent a simple hysterectomy for
non-malignant lesions in the corpus of the uterus. None of these
patients had conditions, such as endometriosis, in which angiogen-
esis may be an important component. Light microscopic
examination conﬁrmed the normal histology.
RNA extraction
Total RNA was extracted from all samples using the acid-guanidi-
nium isothiocyanate-phenol-chloroform method as described
previously (Chomczynski and Sacchi, 1987). Disintegration of the
tissue was achieved by vortexing and by using a Dounce homoge-
niser. The RNA samples were stored in 50 ml diethyl pyrocarbonate
(DEPC) treated distilled water at 7808C. RNAs were further puri-
ﬁed using an RNeasy Mini Protocol for RNA Clean up (Qiagen
Ltd., Crawley, UK) and quantitated in a Genequant spectrophot-
ometer (Pharmacia, St Albans, UK).
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Table 1 Clinicopathological characteristics of the 34 patients whose
cervical cancers were analysed for expression of nine genes implicated in
angiogenesis
Patient characteristics Number
Cell type (WHO-classiﬁcation)
Squamous cell carcinoma 23
Adenocarcinoma 8
Clear cell carcinoma 2
Carcinoid 1
Histological grade
Grade 1 15
Grade 2 14
Grade 3 5
FIGO-stage
Stage IA2 6
Stage IB1 15
Stage IB2 6
Stage IIA 2
Stage IIB 3
Stage III 2
Lymph nodes
Positive/negative 6/28
Lympho-vascular space invasion
Positive/negative 9/25
Recurrent disease during follow-up
Positive/negative 6/28
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Primers and probes were designed using Primer Express software
(PE-ABI). The probes were designed speciﬁcally to span an intron
in order to avoid potential ampliﬁcation of small amounts of
contaminating DNA in the analysed samples. The probes were
labelled at the 5' end with 6-carboxy ﬂuorescein (FAM) and at
the 3' end with 6-carboxy-tetramethyl rhodamine (TAMRA).
Primers and probes were stored at 7208C until use. Table 2 shows
the primers and probe sequences for: VEGF121 (GenBank accession
no: M27281), VEGF165 (GenBank accession no: M27281), VEGF189
(GenBank accession no: M27281), VEGF-C (GenBank accession
no: X94216), eIF-4E (GenBank accession no: NM001968), TSP-2
(GenBank accession no: L12350), b-FGF (GenBank accession no:
M27968), MMP-2 (GenBank accession no: M58552), MMP-9
(GenBank accession no: NM004994), and GAPDH (GenBank
accession no: G04038).
Single-step real-time quantitative RT–PCR
Real-time quantitative RT–PCR analysis was performed using the
Taqman PCR Core Reagent Kit (PE Biosystems). Prior to reverse
transcription, the RNA template was heated for 2 min at 508Ci n
the presence of 0.01 U l
71 uracil N-glycosylase. To prevent
carry-over of contaminating DNA, the reaction was carried out
in the presence of dUTP. Total RNA (100 ng) was reverse tran-
scribed in a 25ml reaction mixture at 608C for 30 min. After
5 min denaturation at 928C, PCR was carried out for 40 cycles
with denaturation at 928C for 20 s and extension at 628C for
60 s in the presence of the ﬂuorescent oligonucleotides indicated
above. RT–PCR analyses were carried out at least twice for each
gene transcript to determine consistency of results, and GAPDH
mRNA was assessed as internal control for RNA quality. Reactions
were recorded and analysed using the ABI 7700 Prism Sequence
detection system (Perkin-Elmer Applied Biosystems, Warrington,
UK). Accurate quantitation was achieved through the generation
of standard curves by serially diluting a known amount of cDNA
from corresponding synthetic RNA and performing Taqman PCR
on the series alongside patient samples. All gene transcript levels
are expressed per mg of RNA.
Preparation of cDNA
Two mg of DNase treated RNA was mixed with 2 ml( 1mg) of
random hexamers in DEPC water, in a total volume of 14 ml.
The mixture was heated at 758C for 15 min and cooled on ice
for 5 min. Subsequently, 5 ml of M-MLV RT reaction buffer, 5 ml
of nucleotide pool and 1 ml of M-MLV RT enzyme was added. This
mixture was left at room temperature for 10 min and incubated at
408C for 50 min. Seventy ﬁve ml of DEPC water was added to
make up a total volume of 100 ml.
Real-time PCR for 18S rRNA
The housekeeping gene 18S rRNA was evaluated in all samples as
internal control. In a total volume of 25 ml the following was added
as reaction mixture: 12.5 ml of TaqMan Universal Master Mix
(Applied Biosystems), 2.5 ul of human 18S rRNA Assay Reagents
(Pre-developed; Applied Biosystems), 1 ul (100 ng) of cDNA and
9 ml of DEPC water. After 2 min at 508C, denaturation was
performed at 958C for 10 min; PCR was carried out for 40 cycles
with denaturation at 958C for 15 s and annealing at 608C for
1 min. The threshold cycle (Ct) for each sample was determined.
Statistical Analysis
The Mann–Whitney U-test was used to compare the means of the
gene expressions between normal and malignant tissues (SPSS soft-
ware, Version 9.0 for Windows, SPSS, Inc, Chicago, IL, USA). We
have used the Spearman’s rank correlation to compare the co-
expression patterns between the normal and the cancer group. A
correlation with a P-value of 50.05 was considered to be signiﬁ-
cant. In addition, the z-test was performed to compare the
Spearman correlation matrices between normal and malignant
(MedCalc, Version 6.0 for Windows, 1998). The two compared
correlation coefﬁcients (r) are transformed into two z values by
this formula:
z  0:5  ln1  rÿln1 ÿ r
which almost follows a normal distribution of mean m, and
variance 1/(n-3), with n the number of individuals in the sample.
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Table 2 Primers/probe sequences used in the real-time quantitative RT–PCR assays to analyse transcription levels of nine genes involved in angiogenesis.
The housekeeping gene GAPDH was also included.
mRNA Primers Probe (5'FAM-3'TAMRA)
VEGF121 Sense: AGCTTCCTACAGCACAACAAATGT TGCAGACCAAAGAAAGATAGAGCAAGACAAGAAA
Antisense: CGCCTCGGCTTGTCACA
VEGF165 Sense: TGTGAATGCAGACCAAAGAAAGA AGAGCAAGACAAGAAAATCCCTGTGGGC
Antisense: GCTTTCTCCGCTCTGAGCAA
VEGF189 Sense: TGTGAATGCAGACCAAAGAAAGA AGAGCAAGACAAGAAAAAAAATCAGTTCGAGGAA
Antisense: CGTTTTTGCCCCTTTCCC
VEGF-C Sense: TCAAGGACAGAAGAGACTATAAAATTTGC ATACACACCTCCCGTGGCATGCATTG
Antisense: ACTCCAAACTCCTTCCCCACAT
eIF-4E Sense: ATGGCGACTGTCGAACCG AACCACCCCTACTCCTAATCCCCCGACT
Antisense: ATTAGATTCCGTTTTCTCCTCTTCTG
TSP-2 Sense: CATCACTGCATCTTTTTGGCA GCCTCCTGCAGCTGAGCTCCTGGT
Antisense: ACCAGCCTCCAGACCATCC
b-FGF Sense: ACCCCGACGGCCGA TCCGGGAGAAGAGCGACCCTCAC
Antisense: TCTTCTGCTTGAAGTTGTAGCTTGA
MMP 2 Sense: CGCTCAGATCCGTGGTGAG TTCTTCTTCAAGGACCGTTCATTTGGC
Antisense: TGTCACGTGGCGTCACAGT
MMP 9 Sense: CCCTGGAGACCTGAGAACCA CCGACAGGCAGCTGGCAGAGGAAT
Antisense: CCCGAGTGTAACCATAGCGG
GAPDH Sense: GAAGGTGAAGGTCGGAGTC CAAGCTTCCCGTTCTCAGCC
Antisense: GAAGATGGTGATGGGATTTC
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D  z1 ÿ z2 and SDDHvariance z1  variance z2
RESULTS
Transcript levels in normal and malignant cervical tissue
Real-time quantitative RT–PCR analysis was performed on mRNA
transcripts of nine genes (VEGF121, VEGF165, VEGF189, VEGF-C,
eIF-4E, b-FGF, TSP-2, MMP-2 and MMP-9) involved in angiogen-
esis and/or lymphangiogenesis as well as tumour cell invasion.
Experiments were repeated at least twice for each gene. GAPDH
was initially considered as an internal control. However, consider-
able variation in mRNA levels were found for this housekeeping
gene. In contrast, all samples showed a threshold cycle between
17 and 18 for 18S rRNA, demonstrating its usefulness as internal
control for quality of RNA.
Figures 1A, B, C show the transcript levels in normal and malig-
nant cervical tissues for the nine genes analysed. All tumour and
normal samples expressed the VEGF-A isoforms in order of
decreasing abundance, 16541214189 (Figure 1A). In normal
cervical tissue, a greater distribution (95% conﬁdence interval
(CI)) was observed for the mRNA copy numbers of the different
VEGF-A splice variants compared to cervical cancer. This may be
due in part to the inﬂuence of the hormonal cycle. The levels of
the different VEGF-A splice variants were signiﬁcantly higher in
malignant compared to normal cervical tissues. There was an 11-
fold increase in the mean copy number of VEGF165, a 23-fold
increase in VEGF121 and a 13-fold increase in VEGF189 in malig-
nant compared to normal tissues. The highest levels of VEGF121,
VEGF165 and VEGF189 mRNA were found in cervical tumours with
lympho-vascular space involvement in the primary tumour, which
is known to be a poor prognostic factor (lympho-vascular space
includes all small vessels, capillaries as well as lymphatic vessels,
present in the primary tumour and the surrounding tissue). All
cervical cancers expressed high levels of VEGF-C, and the levels
were more than 130-fold higher than in normal cervical tissues
(Figure 1B). The highest levels of VEGF-C mRNA were found in
the lymph node-positive group. Of the 18 normal cervical tissues
analysed, only 10 expressed 4100 copies of VEGF-C mRNA/mg
total RNA, suggesting that VEGF-C is not implicated in normal
physiological processes in cervical tissue. Levels of b-FGF mRNA
were similar in normal cervical tissue and early-stage cervical
cancers. However, high levels of b-FGF mRNA were found in the
ﬁve cervical cancers with advanced stage disease. The levels of
TSP-2 and of eIF-4E mRNA were increased four- and seven-fold
respectively in cervical cancer. No differences in the level of
MMP-2 mRNA were found between normal and malignant cervical
tissue. However, an approximately 80-fold increase in MMP-9
mRNA was observed in cervical cancers (Figure 1C).
Using the Mann–Whitney U-test the differences in the means
between the two groups (normal vs cancer) are highly signiﬁcant
(P-values 40.006), except for the genes b-FGF and MMP-2
(respective P-values: 0.336, 0.584) (Figure 1A, B, C).
Gene co-expression patterns in normal and malignant
cervical tissue
Tables 3A and B show the Spearman correlation matrices of gene
co-expressions (with rho and P-values) in normal and malignant
cervical tissue. In normal cervical tissue, a strong co-expression is
observed between the angiogenesis inhibitor TSP-2 and the other
genes analysed. Furthermore, MMP-2 is also strongly co-expressed
with the other genes analysed in normal cervical tissue, except for
MMP-9. In cervical cancer, TSP-2 seems to be strongly co-
expressed only with MMP-2. In both normal and malignant cervi-
cal tissue, signiﬁcant co-expressions were found between the
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Figure 1 (A) Log mRNA copy numbers of the different VEGF-A splice
variants in normal and malignant cervical tissue. (B) Log mRNA copy num-
bers of VEGF-C, b-FGF and Thrombospondin-2 in normal and malignant
cervical tissue. (C) Log mRNA copy numbers of MMP-2, MMP-9 and
eIF-4E in normal and malignant cervical tissue. Error bar: 95% Conﬁdence
Interval for the mean.
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C is strongly co-expressed with all other genes analysed, except for
MMP-9 and eIF4E. However, in cervical cancer, VEGF-C is
strongly co-expressed with MMP-9, VEGF189 and
b-FGF. In addition, MMP-9 is strongly co-expressed with VEGF189
in cervical cancer but not in normal cervical tissue.
To compare the co-expressions between the two groups (normal
vs malignant), the z-statistic of Fischer was used on the Spearman
correlation matrices (Table 4). Of the 36 correlation coefﬁcients, 18
(50%) showed signiﬁcant differences in favour of a higher correla-
tion in the normal group, except for MMP-9/VEGF189.
Although the sample size was smaller for the normal group and
the distribution (95% conﬁdence interval) of quantitative gene
expression levels was broader, we observed a highly consistent
co-expression pattern in the normal cases. This could reﬂect the
housekeeping mode in normal cases.
Differences in gene (co-)expressions between recurrent and
non-recurrent cervical cancers
Six patients (18%) with primary cervical cancer developed recur-
rent disease during a mean follow-up of 27 months. Three
patients were initially diagnosed with early-stage disease, the other
three patients had advanced disease at initial presentation. No
signiﬁcant differences in co-expression patterns were found
between recurrent and non-recurrent cervical cancers. However, a
signiﬁcant difference was found in the mean of expression levels
for TSP-2, between the recurrent and the non-recurrent group
(P-value=0.038; Mann–Whitney U-test). The mean value of
TSP-2 in non-recurrent cases was 4.9610
5 copies mg
71 RNA
(s.d.: +/77.7610
5), and in recurrent cases 1.8610
5 copies/mg
RNA (SD: +/73610
5). This suggests that TSP-2 might play a
crucial role in progression of disease in cervical cancer.
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Table 3 Spearman correlation matrix to assess gene co-expressions (with rho and P-values) in normal (A) and malignant (B) cervical tissue
A. Normal cervical tissue
VEGF165 VEGF121 VEGF189 VEGF-C b-FGF TSP-2 eIF4E MMP-2 MMP-9
VEGF165 rho 1.000
P-value
VEGF121 rho 0.90 1.000
P-value 50.0001
VEGF189 rho 0.49 0.49 1.000
P-value 0.039 0.016
VEGF-C rho 0.81 0.77 0.63 1.000
P-value 50.0001 50.0001 0.005
b-FGF rho 0.83 0.64 0.32 0.83 1.000
P-value 50.0001 0.005 0.191 50.0001
TSP-2 rho 0.86 0.77 0.58 0.92 0.85 1.000
P-value 50.0001 50.0001 0.011 50.0001 50.0001
eIF4E rho 0.56 0.39 0.26 0.48 0.66 0.063 1.000
P-value 0.015 0.109 0.302 0.046 0.003 0.005
MMP-2 rho 0.92 0.78 0.58 0.83 0.87 0.93 0.70 1.000
P-value 50.0001 50.0001 0.012 50.0001 50.0001 50.0001 0.001
MMP-9 rho 0.64 0.55 0.18 0.51 0.56 0.61 0.41 0.53 1.000
P-value 0.004 0.018 0.480 0.032 0.015 0.008 0.093 0.022
A strong co-expression is observed between the angiogenesis inhibitor thrombospondin-2 (TSP-2) and the other genes analysed in normal cervical tissue. P-values in bold
represent highly signiﬁcant co-expressions (P50.0001).
B. Malignant cervical tissue
VEGF165 VEGF121 VEGF189 VEGF-C b-FGF TSP-2 eIF4E MMP-2 MMP-9
VEGF165 rho 1.000
P-value
VEGF121 rho 0.79 1.000
P-value 50.0001
VEGF189 rho 0.66 0.80 1.000
P-value 50.0001 50.0001
VEGF-C rho 0.10 0.36 0.52 1.000
P-value 0.562 0.037 0.002
b-FGF rho 70.07 0.13 0.17 0.63 1.000
P-value 0.714 0.479 0.324 50.0001
TSP-2 rho 0.38 0.27 0.16 0.37 0.34 1.000
P-value 0.028 0.127 0.362 0.032 0.051
eIF4E rho 0.27 0.14 0.01 70.22 70.02 0.08 1.000
P-value 0.119 0.447 0.985 0.207 0.928 0.663
MMP-2 rho 0.19 0.08 70.07 0.31 0.41 0.84 0.03 1.000
P-value 0.270 0.643 0.692 0.075 0.016 50.0001 0.875
MMP-9 rho 0.40 0.51 0.68 0.50 0.07 0.20 70.14 0.09 1.000
P-value 0.018 0.002 50.0001 0.002 0.699 0.257 0.448 0.623
In contrast to normal cervical tissue, TSP-2 seems to be only strongly co-expressed with MMP-2 in malignant cervical tissue. The main difference between normal and malig-
nant cervical tissue is the strong co-expression between MMP-9 and VEGF189 in cervical cancer. P-values in bold represent highly signiﬁcant co-expressions (P50.0001).
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We show here that combined application of real-time quantitative
RT–PCR with correlation matrices of gene expression data allows
us to identify differences in gene co-expression patterns between
normal and malignant cervical tissue.
In vivo and in vitro studies using semi-quantitative techniques
have recently shown that tumours exhibiting high expression levels
of vascular endothelial growth factor (VEGF) have a high meta-
static potential (Potgens et al, 1996; Ohta et al, 1997). In vivo
studies in cervical cancer have demonstrated a signiﬁcant correla-
tion between MVD and VEGF mRNA expression, with the
highest levels in stage I and stage IV disease (Fujimoto et al,
1999; Kodama et al, 1999). VEGF121 and VEGF165 were found to
be the two dominant VEGF-A subtypes with similar expression
levels in normal cervix as well as in cervical cancer. VEGF189 was
barely detectable. In our study, using a fully quantitative RT–
PCR technique, mRNA levels of the different VEGF-A splice
variants were signiﬁcantly higher in malignant compared to normal
cervical tissues, with a more than 10-fold increase in VEGF121,
VEGF165, and VEGF189. Interestingly, the highest levels of VEGF121,
VEGF165 and VEGF189 mRNA were found in cervical tumours
histologically characterised by lympho-vascular space involvement,
which is known to be a poor prognostic factor. In normal cervical
tissue, a greater distribution was observed for the mRNA copy
numbers of the different VEGF-A splice variants compared to
cervical cancer. This may be due in part to the inﬂuence of the
hormonal cycle, however, the co-expression patterns were stronger
and more consistent than in cervical cancer.
We have shown that all tumour and normal samples expressed
the VEGF-A isoforms, 16541214189, in order of decreasing
abundance. This order differs from normal and malignant breast
tissue in which the VEGF121 isoform is most abundant (Scott et
al, 1998). There is evidence that b-FGF mRNA levels are higher
in advanced cervical cancers, regardless of histological type,
suggesting that it may predominantly play a role in the later mole-
cular events which regulate angiogenesis in this particular tumour
(Fujimoto et al, 1997). Furthermore, it has been demonstrated that
VEGF is essential for the initial but not continued growth of
human breast carcinoma cells in vivo, and that other angiogenic
factors, such as b-FGF, can substitute for VEGF during disease
progression (Yoshiji et al, 1997). This is consistent with our ﬁnd-
ings that early-stage cervical cancers had no signiﬁcant increase in
b-FGF mRNA, whereas a signiﬁcant increase was observed in
advanced stage cancers. Elevated levels of eIF-4E have been asso-
ciated with increased growth rates and cell transformation in
HeLa cells (De Benedetti and Rhoads, 1990). It has been suggested
that eIF-4E may regulate expression of genes including angiogenic
factors such as VEGF and b-FGF as well as subsequent tumour
growth (Kevil et al, 1996). In our study, there was a seven-fold
increase in transcript level of eIF-4E in cervical cancer.
Clinical and pathological observations have revealed that lymph
node involvement is one of the earliest features of metastatic
disease, and this certainly holds true for cervical cancer. Blood-
borne tumour cells seed out in the lymphatic hilum, and with
an increasing number of tumour cells in the blood, the frequency
of nodal involvement rises. This occurs particularly in patients with
large volume disease and increased numbers of microvessels in the
primary tumour. A second route is via lymphatic vessels, and this
pathway may be of particular importance in early microdissemina-
tion to lymph nodes (Ohta et al, 2000; reviewed by Van Trappen
and Pepper, 2002). It has recently been demonstrated that primary
solid tumours expressing vascular endothelial growth factors -C
and -D (VEGF-C and -D), induce lymphangiogenesis de novo,
thereby providing a direct conduit for tumour cell dissemination
to lymph nodes (Mandriota et al, 2001; Skobe et al, 2001; Stacker
et al, 2001). In prostatic carcinoma, the expression of VEGF-C
mRNA in the primary tumour is signiﬁcantly higher in lymph
node-positive patients compared to lymph node-negative patients
(Tsurusaki et al, 1999).
Our results have revealed that VEGF-C transcript levels are more
than 130-fold higher in cervical cancer compared to normal cervical
tissues. Using real-time quantitative RT–PCR we found the highest
VEGF-C mRNA levels in the lymph node-positive cervical cancers.
Although VEGF-C is the principal lymphangiogenic growth factor
described to date, it also has angiogenic properties under certain
circumstances, including tumorigenesis (Olofsson et al, 1999). This
implies that VEGF-C may serve to increase both tumour vasculari-
sation and lymphangiogenesis, thereby contributing to the increase
in tumour growth and the formation of metastases.
Proteolytically-mediated extracellular matrix (ECM) degradation
is crucial for angiogenesis as well as for the detachment of malig-
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Table 4 Comparison of the co-expression patterns between the two
groups (normal vs malignant) using the z-statistic of Fischer on the Spear-
man correlation matrices.
Correlation in Correlation in z-statistic
Normal group Cancer group rho and
Co-expression p-value p-value p-value
VEGFC-VEGF165 0.81 0.10 3.17
50.0001 0.562 0.0015**
VEGFC-VEGF121 0.77 0.36 2.08
50.0001 0.037 0.0373***
b-FGF-VEGF165 0.83 70.07 0.97
50.0001 0.714 0.0001*
b-FGF-VEGF121 0.63 0.13 1.97
0.005 0.479 0.0484***
TSP2-VEGF165 0.85 0.38 2.76
50.0001 0.028 0.0058**
TSP2-VEGF121 0.77 0.27 2.40
50.0001 0.127 0.0165***
TSP2-VEGFC 0.92 0.37 3.66
50.0001 0.032 0.0003*
TSP2-b-FGF 0.85 0.34 2.79
50.0001 0.051 0.0052**
eIF-4E-VEGFC 0.48 70.22 2.33
0.046 0.207 0.0197***
eIF-4E-b-FGF 0.66 70.02 2.50
0.003 0.928 0.0125***
eIF-4E-TSP2 0.63 0.08 2.08
0.005 0.663 0.0373***
MMP2-VEGF165 0.92 0.19 4.25
50.0001 0.270 50.00001*
MMP2-VEGF121 0.78 0.08 2.99
50.0001 0.643 50.0028**
MMP2-VEGF189 0.58 70.07 2.33
0.012 0.692 0.0198***
MMP2-VEGFC 0.83 0.31 3.58
50.0001 0.075 0.0003*
MMP2-b-FGF 0.87 0.41 2.85
50.0001 0.016 0.0043**
MMP2-eIF-4E 0.70 0.03 2.69
0.001 0.875 0.0071**
MMP9-VEGF189 0.18 0.68 72.03
0.480 50.0001 0.0422***
Of the 36 correlation coefﬁcients, 18 (50%) showed signiﬁcant differences in favour
of a higher correlation in the normal group. the P-values of the z-statistic with one star
show highly signiﬁcant differences between the two groups, with a signiﬁcant level of
0.1% (P-value 50.001). These correlation coefﬁcients are positive and only highly
signiﬁcant in the normal group. The two stars represent P-value with strong signifi-
cant differences between the two correlations, with a signiﬁcant level of 1%
(P-value50.01). In all cases, correlation coefﬁcients are positive but higher in the
normal group. The P-values of the z-statistic with three stars show signiﬁcant differ-
ences between the two groups with a signiﬁcant level of 5% (P-value 50.05). Almost
all correlations are positive and higher in the normal group, except for MMP9-
VEGF189.
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surrounding stroma (Pepper, 2001). Matrix metalloproteinases
(MMPs) have been heavily implicated in these processes, and are
indispensable for the degradation of native triple-helical collagen,
a major component of ECMs. Two of the best studied MMP’s in
angiogenesis and cancer are MMP-2 and MMP-9 (gelatinase-A
and -B), which amongst other molecules degrade collagen IV,
one of the major components of the basement membrane.
MMP-2 and MMP-9 play an important role in triggering the
angiogenic switch in null mice (reviewed by Pepper, 2001). In
addition, enhanced mRNA and protein expression of both enzymes
has been reported in breast, colon and pancreatic cancer (Campo et
al, 1992). In our study, no differences in MMP-2 were found
between normal and malignant cervical tissue at the mRNA level.
However, an approximately 80-fold increase was observed for
MMP-9 mRNA in cervical cancers. The fact that we observed no
increase in MMP-2 and a marked increase in MMP-9, provides
no information about the status of MMP activation, which from
a mechanistic point of view may be more relevant. Nonetheless,
our ﬁndings have revealed a clear relationship between increased
MMP-9 mRNA and cervical cancer, increasing the probability that
MMP-9 plays a key role in the progression of early-stage cervical
cancer.
In normal cervical tissue, gene co-expression pattern analysis
revealed a strong co-expression between TSP-2, MMP-2 and the
other genes analysed, except for MMP-9. In cervical cancer, TSP-
2 appears only to be co-expressed with MMP-2. The lymphangio-
genic factor VEGF-C is strongly co-expressed with MMP-9,
VEGF189 and b-FGF in cervical cancer. In addition, MMP-9 is
strongly co-expressed with VEGF189 in cervical cancer but not in
normal cervical tissue. Comparison of the co-expression patterns
between the two groups revealed that almost all correlations are
positive and stronger in the normal group, except for the co-
expression MMP-9/VEGF189. Recently, in vivo studies have shown
that colon cancer metastasis results from an alteration in the
balance between the angiogenesis inhibitor thrombospondin-2
and the angiogenic growth factor VEGF189 (Tokunaga et al,
1998). We found a signiﬁcant difference in the mean of expression
levels for thrombospondin-2 between recurrent and non-recurrent
cancer cases, with the lowest levels in the recurrent cases. VEGF189
has been shown to correlate with poor prognosis in colon and lung
cancer (Oshika et al, 1998; Tokunaga et al, 1998), and VEGF-C
may facilitate lymphatic spread (Mandriota et al, 2001; Skobe et
al, 2001; Stacker et al, 2001). In our study, both VEGF189 and
VEGF-C appear to be strongly co-expressed with MMP-9 in cervi-
cal cancer but not in normal cervical tissue.
In this report, we described the combined application of fully
quantitative gene expression data with correlation matrices. This
approach revealed different co-expression patterns between normal
and malignant cervical tissue. This combined molecular-statistical
model could be applied to several other cancers or other sets of
genes.
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